Key Highlights
● Net sales were US$14.41bn, up 3% in dollars and 1% in constant currencies.
● Kisqali sales rose 43% in constant currencies to US$1.7bn.
● Entresto, hit by generic entry, fell 51% in constant currencies.
● Reported net debt rose to US$39.4bn from US$21.9bn at the end of 2025.
Novartis AG (NYSE:NVS) is a Swiss company, and its American depositary shares trade on the New York Stock Exchange as NVS. The cover page of its 2025 annual report on Form 20-F states that each ADS represents one ordinary share, so the ratio is one to one, and that the ordinary shares, of nominal value CHF 0.49 and coded NOVN, are registered with the SEC only in connection with the ADSs. The company reports in US dollars.
Second-quarter results
Net sales were US$14.41bn, up 3% in dollars and 1% in constant currencies, against US$14.05bn. Operating income edged down 2% to US$4.75bn, and net income fell 19% to US$3.26bn, with earnings per share of US$1.71 against US$2.07. Core operating income was flat at US$5.94bn, a core margin of 41.2% against 42.2%. Core earnings per share were US$2.41 against US$2.42. For the first half, net sales were US$27.52bn, up 1% but down 2% in constant currencies, and core operating income fell 6% to US$10.84bn. Chief executive Vas Narasimhan described a solid quarter and a return to sales growth. For the half, net income was US$6.41bn, down 16%, with earnings per share of US$3.37 against US$3.91 and core earnings per share of US$4.39 against US$4.69.
Growth brands against generics
Volume added 18 percentage points to second-quarter sales, but generic competition subtracted 14 points, pricing 3 points and currency added 2. Kisqali sales rose 43% in constant currencies to US$1.7bn, Kesimpta 32% to US$1.42bn, Cosentyx 10% to US$1.82bn, Pluvicto 43% to US$651m, Scemblix 89% to US$562m and Leqvio 59% to US$480m. Entresto, hit by generic entry, fell 51% in constant currencies to US$1.18bn. The pattern is that newer products are replacing a large, ageing franchise, and the company reports that it is doing so at a net positive rate this quarter, though only just. The company says Kisqali grew in all regions with market share gains in early breast cancer, and that Pluvicto demand was strong in the pre-taxane metastatic prostate cancer setting in the United States.
Cash, debt and acquisitions
Reported free cash flow was US$5.56bn in the quarter, 12% lower, and US$8.89bn for the half. Reported net debt rose to US$39.4bn at 30 June 2026 from US$21.9bn at the end of 2025. The company attributes this to US$15.3bn of acquisition, intangible and related outflows, a US$9.1bn annual dividend payment and US$3.1bn of treasury share outflows, partly offset by free cash flow. Completed deals in the quarter included Pikavation Therapeutics and Excellergy, while the Myricx Bio acquisition is expected to close in the second half of 2026.
The Generic Hole Narrows, but Debt and Falling Core Profit Raise the Stakes
Guidance, reaffirmed in the release, is for low single-digit net sales growth and a low single-digit decline in core operating income in constant currencies for 2026, with currency expected to add about one percentage point to each if mid-July rates hold. Stated risks include pricing pressure, loss of patent protection, trial outcomes, deal integration, cybersecurity, tariffs and exchange rates. The quarter shows the generic hole narrowing as growth brands scale, while higher debt and falling core profit leave execution on pipeline readouts and new launches important. Management expects a Phase III zigakibart readout in the first half of 2027, and a del-zota application under FDA review for accelerated approval.






Please wait processing your request...